Loading…
Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Immune checkpoint inhibitors (ICIs) have been increasingly applied in the treatment of several kinds of malignancies. Some clinical demographic characteristics were reported to be associated with the ICIs efficacy. The purpose of our current meta-analysis was to clearly evaluated the relationship be...
Saved in:
| Published in: | Journal of translational medicine 2020-06, Vol.18 (1), p.235-235, Article 235 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c563t-9357b46f694b2099112d31d773f231f4f00f87957dc36a2853caecdccc6e00d83 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c563t-9357b46f694b2099112d31d773f231f4f00f87957dc36a2853caecdccc6e00d83 |
| container_end_page | 235 |
| container_issue | 1 |
| container_start_page | 235 |
| container_title | Journal of translational medicine |
| container_volume | 18 |
| creator | An, Yue Wu, Zhonghua Wang, Ningning Yang, Zhidong Li, Yue Xu, Boyang Sun, Mingjun |
| description | Immune checkpoint inhibitors (ICIs) have been increasingly applied in the treatment of several kinds of malignancies. Some clinical demographic characteristics were reported to be associated with the ICIs efficacy. The purpose of our current meta-analysis was to clearly evaluated the relationship between BMI and ICIs efficacy for cancer patients receiving immunotherapy.
A systematic search of Pubmed, EMBASE and conference proceedings was performed to investigate the influence of BMI on ICIs efficacy. Pooled analysis for overall survival (OS), progression-free survival (PFS) and immune-related adverse effects (IRAEs) were analyzed in current study.
A total of 13 eligible studies comprising 5279 cancer patients treated with ICIs were included in the analysis. The pooled analysis showed there is positive association between high BMI and improved OS and PFS among patients with ICIs treatment (OS: HR = 0.62, 95% CI 0.55-0.71, P |
| doi_str_mv | 10.1186/s12967-020-02404-x |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_bb3c4274a3734664b322e6d47dbd9711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A627410717</galeid><doaj_id>oai_doaj_org_article_bb3c4274a3734664b322e6d47dbd9711</doaj_id><sourcerecordid>A627410717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-9357b46f694b2099112d31d773f231f4f00f87957dc36a2853caecdccc6e00d83</originalsourceid><addsrcrecordid>eNptUstuFDEQHCEQCYEf4IAsccllgl8zXnNAWkU8IkXiAmfLY_fsepmxF9uzj5_hW_HuhpAgZFlttauq3e2qqtcEXxEya98lQmUrakxx2RzzevekOidcyLqZifbpg_NZ9SKlFS6ohsvn1RmjDaO0ac6rX_OUgnE6u-BRB3kLUGKwezTqlJDzFnZIe4vSFDduowcUpmzCCAn1ISKjvYGI1oUPPieUI-gMFm1dXiI3jpMHZJZgfqyD87nILV3ncojpPdIo7VOGsVANirBxsD0WGiHrWns97JNLL6tnvR4SvLqLF9X3Tx-_XX-pb79-vrme39amaVmuJWtEx9u-lbyjWEpCqGXECsF6ykjPe4z7mZCNsIa1ms4aZjQYa4xpAWM7YxfVzUnXBr1S6-hGHfcqaKeOiRAXSsfy0AFU1zHDqeCaCcbblndlktBaLmxnpSCkaH04aa2nbgRrymCiHh6JPr7xbqkWYaMElaRhB4HLO4EYfk6QshpdMjAM2kOYkqK8fLyUuJEF-vYf6CpMsQzviOLl6yVjf1ELXRpwvg-lrjmIqnlbWiFYEFFQV_9BlWVhdCZ46F3JPyLQE8HEkFKE_r5HgtXBoerkUFUcqo4OVbtCevNwOveUP5ZkvwHlLOPb</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2414876933</pqid></control><display><type>article</type><title>Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>An, Yue ; Wu, Zhonghua ; Wang, Ningning ; Yang, Zhidong ; Li, Yue ; Xu, Boyang ; Sun, Mingjun</creator><creatorcontrib>An, Yue ; Wu, Zhonghua ; Wang, Ningning ; Yang, Zhidong ; Li, Yue ; Xu, Boyang ; Sun, Mingjun</creatorcontrib><description>Immune checkpoint inhibitors (ICIs) have been increasingly applied in the treatment of several kinds of malignancies. Some clinical demographic characteristics were reported to be associated with the ICIs efficacy. The purpose of our current meta-analysis was to clearly evaluated the relationship between BMI and ICIs efficacy for cancer patients receiving immunotherapy.
A systematic search of Pubmed, EMBASE and conference proceedings was performed to investigate the influence of BMI on ICIs efficacy. Pooled analysis for overall survival (OS), progression-free survival (PFS) and immune-related adverse effects (IRAEs) were analyzed in current study.
A total of 13 eligible studies comprising 5279 cancer patients treated with ICIs were included in the analysis. The pooled analysis showed there is positive association between high BMI and improved OS and PFS among patients with ICIs treatment (OS: HR = 0.62, 95% CI 0.55-0.71, P < 0.0001; I
= 26.3%, P = 0.202); PFS: HR = 0.71, 95% CI 0.61-0.83, P < 0.0001; I
= 0%, P = 0.591). There is no significant difference between the incidence of all grade IRAEs between obese, overweight patients and normal patients (Overweight vs Normal: pooled RR = 1.28, 95% CI 0.76- 2.18, P = 0.356; Obese vs Normal: pooled RR = 1.36, 95% CI 0.85- 2.17, P = 0.207).
An improved OS and PFS were observed in patients with high BMI after receiving ICIs treatment compared with patients of low BMI. No significant association between BMI and incidence of IRAEs was found in cancer patients after ICIs treatment.</description><identifier>ISSN: 1479-5876</identifier><identifier>EISSN: 1479-5876</identifier><identifier>DOI: 10.1186/s12967-020-02404-x</identifier><identifier>PMID: 32532255</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Atezolizumab ; Avelumab ; Biomarkers ; Body Mass Index ; Body weight ; Cancer ; Cancer patients ; Cancer therapies ; Drug therapy ; Drug-Related Side Effects and Adverse Reactions ; Durvalumab ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Ipilimumab ; Medical prognosis ; Medical research ; Melanoma ; Meta-analysis ; Neoplasms - complications ; Neoplasms - drug therapy ; Nivolumab ; Obesity ; Oncology ; Overall survival ; Overweight ; Patient outcomes ; Patients ; Pembrolizumab ; Progression-free survival ; Quality ; Studies ; Survival</subject><ispartof>Journal of translational medicine, 2020-06, Vol.18 (1), p.235-235, Article 235</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c563t-9357b46f694b2099112d31d773f231f4f00f87957dc36a2853caecdccc6e00d83</citedby><cites>FETCH-LOGICAL-c563t-9357b46f694b2099112d31d773f231f4f00f87957dc36a2853caecdccc6e00d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291531/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2414876933?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32532255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>An, Yue</creatorcontrib><creatorcontrib>Wu, Zhonghua</creatorcontrib><creatorcontrib>Wang, Ningning</creatorcontrib><creatorcontrib>Yang, Zhidong</creatorcontrib><creatorcontrib>Li, Yue</creatorcontrib><creatorcontrib>Xu, Boyang</creatorcontrib><creatorcontrib>Sun, Mingjun</creatorcontrib><title>Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis</title><title>Journal of translational medicine</title><addtitle>J Transl Med</addtitle><description>Immune checkpoint inhibitors (ICIs) have been increasingly applied in the treatment of several kinds of malignancies. Some clinical demographic characteristics were reported to be associated with the ICIs efficacy. The purpose of our current meta-analysis was to clearly evaluated the relationship between BMI and ICIs efficacy for cancer patients receiving immunotherapy.
A systematic search of Pubmed, EMBASE and conference proceedings was performed to investigate the influence of BMI on ICIs efficacy. Pooled analysis for overall survival (OS), progression-free survival (PFS) and immune-related adverse effects (IRAEs) were analyzed in current study.
A total of 13 eligible studies comprising 5279 cancer patients treated with ICIs were included in the analysis. The pooled analysis showed there is positive association between high BMI and improved OS and PFS among patients with ICIs treatment (OS: HR = 0.62, 95% CI 0.55-0.71, P < 0.0001; I
= 26.3%, P = 0.202); PFS: HR = 0.71, 95% CI 0.61-0.83, P < 0.0001; I
= 0%, P = 0.591). There is no significant difference between the incidence of all grade IRAEs between obese, overweight patients and normal patients (Overweight vs Normal: pooled RR = 1.28, 95% CI 0.76- 2.18, P = 0.356; Obese vs Normal: pooled RR = 1.36, 95% CI 0.85- 2.17, P = 0.207).
An improved OS and PFS were observed in patients with high BMI after receiving ICIs treatment compared with patients of low BMI. No significant association between BMI and incidence of IRAEs was found in cancer patients after ICIs treatment.</description><subject>Analysis</subject><subject>Atezolizumab</subject><subject>Avelumab</subject><subject>Biomarkers</subject><subject>Body Mass Index</subject><subject>Body weight</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Drug therapy</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Durvalumab</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors</subject><subject>Immunotherapy</subject><subject>Ipilimumab</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Melanoma</subject><subject>Meta-analysis</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - drug therapy</subject><subject>Nivolumab</subject><subject>Obesity</subject><subject>Oncology</subject><subject>Overall survival</subject><subject>Overweight</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Pembrolizumab</subject><subject>Progression-free survival</subject><subject>Quality</subject><subject>Studies</subject><subject>Survival</subject><issn>1479-5876</issn><issn>1479-5876</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUstuFDEQHCEQCYEf4IAsccllgl8zXnNAWkU8IkXiAmfLY_fsepmxF9uzj5_hW_HuhpAgZFlttauq3e2qqtcEXxEya98lQmUrakxx2RzzevekOidcyLqZifbpg_NZ9SKlFS6ohsvn1RmjDaO0ac6rX_OUgnE6u-BRB3kLUGKwezTqlJDzFnZIe4vSFDduowcUpmzCCAn1ISKjvYGI1oUPPieUI-gMFm1dXiI3jpMHZJZgfqyD87nILV3ncojpPdIo7VOGsVANirBxsD0WGiHrWns97JNLL6tnvR4SvLqLF9X3Tx-_XX-pb79-vrme39amaVmuJWtEx9u-lbyjWEpCqGXECsF6ykjPe4z7mZCNsIa1ms4aZjQYa4xpAWM7YxfVzUnXBr1S6-hGHfcqaKeOiRAXSsfy0AFU1zHDqeCaCcbblndlktBaLmxnpSCkaH04aa2nbgRrymCiHh6JPr7xbqkWYaMElaRhB4HLO4EYfk6QshpdMjAM2kOYkqK8fLyUuJEF-vYf6CpMsQzviOLl6yVjf1ELXRpwvg-lrjmIqnlbWiFYEFFQV_9BlWVhdCZ46F3JPyLQE8HEkFKE_r5HgtXBoerkUFUcqo4OVbtCevNwOveUP5ZkvwHlLOPb</recordid><startdate>20200612</startdate><enddate>20200612</enddate><creator>An, Yue</creator><creator>Wu, Zhonghua</creator><creator>Wang, Ningning</creator><creator>Yang, Zhidong</creator><creator>Li, Yue</creator><creator>Xu, Boyang</creator><creator>Sun, Mingjun</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200612</creationdate><title>Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis</title><author>An, Yue ; Wu, Zhonghua ; Wang, Ningning ; Yang, Zhidong ; Li, Yue ; Xu, Boyang ; Sun, Mingjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-9357b46f694b2099112d31d773f231f4f00f87957dc36a2853caecdccc6e00d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Analysis</topic><topic>Atezolizumab</topic><topic>Avelumab</topic><topic>Biomarkers</topic><topic>Body Mass Index</topic><topic>Body weight</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Drug therapy</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Durvalumab</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors</topic><topic>Immunotherapy</topic><topic>Ipilimumab</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Melanoma</topic><topic>Meta-analysis</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - drug therapy</topic><topic>Nivolumab</topic><topic>Obesity</topic><topic>Oncology</topic><topic>Overall survival</topic><topic>Overweight</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Pembrolizumab</topic><topic>Progression-free survival</topic><topic>Quality</topic><topic>Studies</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>An, Yue</creatorcontrib><creatorcontrib>Wu, Zhonghua</creatorcontrib><creatorcontrib>Wang, Ningning</creatorcontrib><creatorcontrib>Yang, Zhidong</creatorcontrib><creatorcontrib>Li, Yue</creatorcontrib><creatorcontrib>Xu, Boyang</creatorcontrib><creatorcontrib>Sun, Mingjun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Journal of translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>An, Yue</au><au>Wu, Zhonghua</au><au>Wang, Ningning</au><au>Yang, Zhidong</au><au>Li, Yue</au><au>Xu, Boyang</au><au>Sun, Mingjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis</atitle><jtitle>Journal of translational medicine</jtitle><addtitle>J Transl Med</addtitle><date>2020-06-12</date><risdate>2020</risdate><volume>18</volume><issue>1</issue><spage>235</spage><epage>235</epage><pages>235-235</pages><artnum>235</artnum><issn>1479-5876</issn><eissn>1479-5876</eissn><abstract>Immune checkpoint inhibitors (ICIs) have been increasingly applied in the treatment of several kinds of malignancies. Some clinical demographic characteristics were reported to be associated with the ICIs efficacy. The purpose of our current meta-analysis was to clearly evaluated the relationship between BMI and ICIs efficacy for cancer patients receiving immunotherapy.
A systematic search of Pubmed, EMBASE and conference proceedings was performed to investigate the influence of BMI on ICIs efficacy. Pooled analysis for overall survival (OS), progression-free survival (PFS) and immune-related adverse effects (IRAEs) were analyzed in current study.
A total of 13 eligible studies comprising 5279 cancer patients treated with ICIs were included in the analysis. The pooled analysis showed there is positive association between high BMI and improved OS and PFS among patients with ICIs treatment (OS: HR = 0.62, 95% CI 0.55-0.71, P < 0.0001; I
= 26.3%, P = 0.202); PFS: HR = 0.71, 95% CI 0.61-0.83, P < 0.0001; I
= 0%, P = 0.591). There is no significant difference between the incidence of all grade IRAEs between obese, overweight patients and normal patients (Overweight vs Normal: pooled RR = 1.28, 95% CI 0.76- 2.18, P = 0.356; Obese vs Normal: pooled RR = 1.36, 95% CI 0.85- 2.17, P = 0.207).
An improved OS and PFS were observed in patients with high BMI after receiving ICIs treatment compared with patients of low BMI. No significant association between BMI and incidence of IRAEs was found in cancer patients after ICIs treatment.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>32532255</pmid><doi>10.1186/s12967-020-02404-x</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-5876 |
| ispartof | Journal of translational medicine, 2020-06, Vol.18 (1), p.235-235, Article 235 |
| issn | 1479-5876 1479-5876 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_bb3c4274a3734664b322e6d47dbd9711 |
| source | Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3) |
| subjects | Analysis Atezolizumab Avelumab Biomarkers Body Mass Index Body weight Cancer Cancer patients Cancer therapies Drug therapy Drug-Related Side Effects and Adverse Reactions Durvalumab Humans Immune Checkpoint Inhibitors Immunotherapy Ipilimumab Medical prognosis Medical research Melanoma Meta-analysis Neoplasms - complications Neoplasms - drug therapy Nivolumab Obesity Oncology Overall survival Overweight Patient outcomes Patients Pembrolizumab Progression-free survival Quality Studies Survival |
| title | Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T15%3A23%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20body%20mass%20index%20and%20survival%20outcomes%20for%20cancer%20patients%20treated%20with%20immune%20checkpoint%20inhibitors:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Journal%20of%20translational%20medicine&rft.au=An,%20Yue&rft.date=2020-06-12&rft.volume=18&rft.issue=1&rft.spage=235&rft.epage=235&rft.pages=235-235&rft.artnum=235&rft.issn=1479-5876&rft.eissn=1479-5876&rft_id=info:doi/10.1186/s12967-020-02404-x&rft_dat=%3Cgale_doaj_%3EA627410717%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c563t-9357b46f694b2099112d31d773f231f4f00f87957dc36a2853caecdccc6e00d83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2414876933&rft_id=info:pmid/32532255&rft_galeid=A627410717&rfr_iscdi=true |